Public or Private?

Myriad CEO Peter Meldrum wrote into the New York Times in a June 20 letter, to highlight that while the Supreme Court invalidated the company's patent claims of isolated gene sequences, the court upheld several claims on synthetic DNA. In addition, he underscores the importance of diagnostic method patents.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: factors influencing retrotransposon integration sites, and more.

A bioethicist argues for the responsible use of germline gene editing.

Some breweries are using DNA-based testing to determine whether unwanted bacteria are affecting their beers, The Verge reports.

Standardized N-of-1 trials will be needed to test out personalized medicines, writes Nicholas Schork from the J. Craig Venter Institute at Nature.